Newton, Inc. (formerly Neurolens) announced findings from a retrospective study of 96,745 patient records which demonstrate statistically significant symptom improvement among patients prescribed Neurolens lenses with Contoured Prism technology. 

Key findings from the study showed a 41% improvement in headache scores; 53% improvement in neck and shoulder stiffness scores; 27% improvement in tired eyes symptom scores; and 28% improvement in overall symptom scores. Based on the study findings, the company said clinicians may consider Neurolens for patients presenting with persistent headaches associated with near work or digital device use; neck and shoulder tension that worsens throughout the day; and visual fatigue and tired eyes, particularly toward end of day. 

"This is the largest real-world data set examining prism-based treatments for binocular vision anomalies to date," said Newton Director of Clinical Affairs Dr. Sumeer Singh, in a press release. "The results provide compelling evidence that Neurolens with Contoured Prism offers enhanced therapeutic benefit." 

The study, authored by Dr. Singh, utilized clinical data from patients at Neurolens provider locations collected between September 2023 and October 2025. To access the full whitepaper, click here. 

The company also noted that in a 2024 peer-reviewed, randomized, controlled, double-masked, crossover trial published in Translational Vision Science & Technology, Neurolens demonstrated a high level of impact using the Headache Impact Test, or HIT-6 questionnaire. According to the company, Neurolens has also been shown to significantly reduce “prism creep”—the tendency for patients to require increasing amounts of prism correction at subsequent visits to maintain visual comfort benefit. OM